期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 61, 期 8, 页码 3296-3308出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b01769
关键词
-
Alzheimer's disease (AD) is characterized by accumulation of beta-amyloid (A beta) plaques and neurofibrillary tau tangles in the brain. beta-Site amyloid precursor protein cleaving enzyme 1 (BACE1) plays a key role in the generation of A beta fragments via extracellular cleavage of the amyloid precursor protein (APP). We became interested in developing a BACE1 PET ligand to facilitate clinical assessment of BACE1 inhibitors and explore its potential in the profiling and selection of patients for AD trials. Using a set of PET ligand design parameters, compound 3 (PF-06684511) was rapidly identified as a lead with favorable in vitro attributes and structural handles for PET radiolabeling. Further evaluation in an LC-MS/MS cold tracer study in rodents revealed high specific binding to BACE1 in brain. Upon radiolabeling, [F-18]3 demonstrated favorable brain in nonhuman primate (NHP), suggesting its potential for imaging BACE1 in humans. uptake and high in vivo specificity in nonhuman primate (NHP), suggesting its potential for imaging BACE1 in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据